FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010758493> ?p ?o ?g. }

• W2010758493 endingPage "999" @default.
• W2010758493 startingPage "993" @default.
• W2010758493 abstract "Background Schizophrenia is associated with immune system dysfunction, including abnormal blood immune cell parameters. We performed a meta-analysis of these associations, considering the effect of clinical status and antipsychotic treatment following an acute exacerbation of psychosis. Methods We identified articles by searching PubMed, PsycINFO, and Thomson Reuters (formerly ISI) Web of Knowledge and the reference lists of identified studies. Results Sixteen studies of blood lymphocytes met the inclusion criteria. There was insufficient data for a meta-analysis of the mononuclear phagocytic system. In cross-sectional studies, there was a significant increase in the CD4% and CD56% in acutely relapsed inpatients. Absolute levels of total lymphocytes, CD3, and CD4, and the CD4/CD8 ratio were significantly increased, and the CD3% was significantly decreased in drug-native first-episode psychosis. In longitudinal studies, the CD4/CD8 ratio appeared to be state-related markers, as it decreased following antipsychotic treatment for acute exacerbations of psychosis. Absolute CD56 levels appeared to be a trait marker, as levels significantly increased following antipsychotic treatment for relapse. Conclusions Blood lymphocyte abnormalities in drug-naïve first-episode psychosis suggest an effect that may be independent of antipsychotic medications. While some parameters (CD4/CD8) may be state markers for acute exacerbations of psychosis, others (CD56) may be trait markers; however, more longitudinal studies are needed. Although these findings could provide the basis for future hypothesis testing, a relatively small number of studies and subjects, lack of correlative data with clinical features, and inadequate consideration of potential confounding factors limit the results. Schizophrenia is associated with immune system dysfunction, including abnormal blood immune cell parameters. We performed a meta-analysis of these associations, considering the effect of clinical status and antipsychotic treatment following an acute exacerbation of psychosis. We identified articles by searching PubMed, PsycINFO, and Thomson Reuters (formerly ISI) Web of Knowledge and the reference lists of identified studies. Sixteen studies of blood lymphocytes met the inclusion criteria. There was insufficient data for a meta-analysis of the mononuclear phagocytic system. In cross-sectional studies, there was a significant increase in the CD4% and CD56% in acutely relapsed inpatients. Absolute levels of total lymphocytes, CD3, and CD4, and the CD4/CD8 ratio were significantly increased, and the CD3% was significantly decreased in drug-native first-episode psychosis. In longitudinal studies, the CD4/CD8 ratio appeared to be state-related markers, as it decreased following antipsychotic treatment for acute exacerbations of psychosis. Absolute CD56 levels appeared to be a trait marker, as levels significantly increased following antipsychotic treatment for relapse. Blood lymphocyte abnormalities in drug-naïve first-episode psychosis suggest an effect that may be independent of antipsychotic medications. While some parameters (CD4/CD8) may be state markers for acute exacerbations of psychosis, others (CD56) may be trait markers; however, more longitudinal studies are needed. Although these findings could provide the basis for future hypothesis testing, a relatively small number of studies and subjects, lack of correlative data with clinical features, and inadequate consideration of potential confounding factors limit the results." @default.
• W2010758493 created "2016-06-24" @default.
• W2010758493 creator A5011046814 @default.
• W2010758493 creator A5035142853 @default.
• W2010758493 creator A5054796938 @default.
• W2010758493 creator A5062986431 @default.
• W2010758493 creator A5071952329 @default.
• W2010758493 date "2013-05-01" @default.
• W2010758493 modified "2023-10-01" @default.
• W2010758493 title "Meta-Analysis of Lymphocytes in Schizophrenia: Clinical Status and Antipsychotic Effects" @default.
• W2010758493 cites W1213337631 @default.
• W2010758493 cites W1964366887 @default.
• W2010758493 cites W1968374987 @default.
• W2010758493 cites W1969763675 @default.
• W2010758493 cites W1969922010 @default.
• W2010758493 cites W1970076965 @default.
• W2010758493 cites W1970343520 @default.
• W2010758493 cites W1971002170 @default.
• W2010758493 cites W1978238793 @default.
• W2010758493 cites W1979480220 @default.
• W2010758493 cites W1983431134 @default.
• W2010758493 cites W1984342992 @default.
• W2010758493 cites W1984874016 @default.
• W2010758493 cites W1988404229 @default.
• W2010758493 cites W1997080110 @default.
• W2010758493 cites W2001358364 @default.
• W2010758493 cites W2006031776 @default.
• W2010758493 cites W2007070202 @default.
• W2010758493 cites W2009381801 @default.
• W2010758493 cites W2010522523 @default.
• W2010758493 cites W2012520574 @default.
• W2010758493 cites W2014596655 @default.
• W2010758493 cites W2016501123 @default.
• W2010758493 cites W2018838561 @default.
• W2010758493 cites W2019516939 @default.
• W2010758493 cites W2019613846 @default.
• W2010758493 cites W2023121190 @default.
• W2010758493 cites W2036194983 @default.
• W2010758493 cites W2037762661 @default.
• W2010758493 cites W2042755650 @default.
• W2010758493 cites W2043008513 @default.
• W2010758493 cites W2043722514 @default.
• W2010758493 cites W2050621916 @default.
• W2010758493 cites W2052960151 @default.
• W2010758493 cites W2053195641 @default.
• W2010758493 cites W2053327244 @default.
• W2010758493 cites W2058367390 @default.
• W2010758493 cites W2058563407 @default.
• W2010758493 cites W2058788536 @default.
• W2010758493 cites W2061678770 @default.
• W2010758493 cites W2066738417 @default.
• W2010758493 cites W2069272538 @default.
• W2010758493 cites W2072328883 @default.
• W2010758493 cites W2077217095 @default.
• W2010758493 cites W2079254246 @default.
• W2010758493 cites W2080978755 @default.
• W2010758493 cites W2082535880 @default.
• W2010758493 cites W2083391392 @default.
• W2010758493 cites W2088018499 @default.
• W2010758493 cites W2090881685 @default.
• W2010758493 cites W2092495736 @default.
• W2010758493 cites W2093050404 @default.
• W2010758493 cites W2098597355 @default.
• W2010758493 cites W2104487731 @default.
• W2010758493 cites W2108598556 @default.
• W2010758493 cites W2114565473 @default.
• W2010758493 cites W2115088255 @default.
• W2010758493 cites W2119656629 @default.
• W2010758493 cites W2120306544 @default.
• W2010758493 cites W2127020388 @default.
• W2010758493 cites W2127205775 @default.
• W2010758493 cites W2137972136 @default.
• W2010758493 cites W2143065529 @default.
• W2010758493 cites W2149368476 @default.
• W2010758493 cites W2150126423 @default.
• W2010758493 cites W2160506388 @default.
• W2010758493 cites W2169847130 @default.
• W2010758493 cites W2170561948 @default.
• W2010758493 cites W2171149822 @default.
• W2010758493 cites W2246471911 @default.
• W2010758493 cites W2402872287 @default.
• W2010758493 cites W2415357004 @default.
• W2010758493 cites W26575043 @default.
• W2010758493 doi "https://doi.org/10.1016/j.biopsych.2012.09.007" @default.
• W2010758493 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3816144" @default.
• W2010758493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23062357" @default.
• W2010758493 hasPublicationYear "2013" @default.
• W2010758493 type Work @default.
• W2010758493 sameAs 2010758493 @default.
• W2010758493 citedByCount "161" @default.
• W2010758493 countsByYear W20107584932013 @default.
• W2010758493 countsByYear W20107584932014 @default.
• W2010758493 countsByYear W20107584932015 @default.
• W2010758493 countsByYear W20107584932016 @default.
• W2010758493 countsByYear W20107584932017 @default.
• W2010758493 countsByYear W20107584932018 @default.
• W2010758493 countsByYear W20107584932019 @default.
• W2010758493 countsByYear W20107584932020 @default.

• next